DNLI News and Press, Denali Therapeutics Inc.

2026-06-23 10:56:54 ET Shares of Denali Therapeutics Inc. (NASDAQ: DNLI) traded at a new 52-week high today and are currently trading at $24.95. So far today, approximately 315.98k shares have been exchanged, as compared to an average 30-day volume of 1.87M shares. Denali Therapeuti...

2026-06-22 10:15:10 ET Bernstein analyst issues HOLD recommendation for DNLI on June 22, 2026 01:26PM ET. The previous analyst recommendation was Hold. DNLI was trading at $24 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2026-06-18 08:49:03 ET More on Denali Therapeutics Denali Therapeutics Inc. (DNLI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript De...

Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases Denali was awarded Priority Review Voucher following FDA approval of AVLAYAH™, the first FDA-appro...

2026-06-17 11:17:43 ET Denali Therapeutics Inc. (NASDAQ: DNLI) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 7.39% on the day to $23.55. Denali Therapeutics Inc. is a biopharmaceutical firm, founded i...

2026-06-05 17:32:54 ET Denali Therapeutics Inc. (DNLI) Jefferies Global Healthcare Conference 2026 June 4, 2026 8:45 AM EDT... Read the full article on Seeking Alpha For further details see: Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2...

2026-05-27 07:54:16 ET The last time I spoke about Denali Therapeutics ( DNLI ) it was with a Seeking Alpha article entitled " Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment ." With respect to this article, I mentioned that the company had...

2026-05-26 08:11:55 ET Last time I wrote about Biogen Inc. ( BIIB ) was at the end of 2025 , in the article " Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge ."... Read the full article on Seeking Alpha For further details see: Leqembi Is...

2026-05-22 16:15:02 ET from Morgan Stanley issued a price target of $35.00 for DNLI on 2026-05-22 18:32:02. The adjusted price target was set to $35.00. At the time of the announcement, DNLI was trading at $18.64. The overall price target consensus is at $31.80 with high...

2026-05-22 07:01:46 ET More on Biogen, Denali Therapeutics Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript Denali Therapeutics Inc. (DNLI) P...